Clinical trial NCT05165147: Analysis the Positive Rate of Tumor Markers Among Physical Examination Population
Official title: Analysis the Positive Status of Tumor Markers Among Physical Examination Population in a Tertiary Grade A Class Hospital
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tumor
Keywords: physical examination population
tumor marker
TM
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2021-12-21
Enrollment: 26891
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: rom January 2019 to December 2019, who underwent physical examination in Peking University Third Hospital were included in the study.

Brief summary: To analyze the positive rate of tumor markers (TM) among health examination population in a tertiary grade A class hospital, compare the differences between different age and sex groups, and explore the possible influencing factors of TM positive.

Detailed description: From January 2019 to December 2019, who underwent physical examination in Peking University Third Hospital were included in the study. The expression levels of carcinoembryonic antigen (CEA),α-fetoprotein (AFP), carbohydrate antigen 19-9 (CA 19-9), carbohydrate antigen-125 (CA-125), carbohydrate antigen 72-4(CA 72-4), carbohydrate antigen 15-3 (CA 15-3), carbohydrate antigen 242(CA 242), squamous cell carcinoma antigen（SCC）, CYFRA21-1, total prostate-specific antigen (TPSA ) , free prostate-specific antigen(FPSA), neuron specific enolase(NSE) were detected by Electro chemistry luminescence method. The positive rates of TM were analyzed by descriptive statistical method Explore. The differences between different age and sex groups and the influencing factors were explored by statistic by Inferential statistical method.

Eligibility criteria: Inclusion Criteria:

* Those who have taken a physical examination and performed at least one TM test

Exclusion Criteria:

* Basic information is missing and cannot be retrieved
* The patient was diagnosed with malignant tumor before examination
* Those who have not done any TM tests

Primary outcomes:
measure: the positive rate of carcinoembryonic antigen（CEA）
timeFrame: 2019.01.01-2019.12.31
measure: the positive rate of α-fetoprotein（AFP）
timeFrame: 2019.01.01-2019.12.31
measure: the positive rate of carbohydrate antigen 19-9（CA 19-9）
timeFrame: 2019.01.01-2019.12.31
measure: the positive rate of carbohydrate antigen 125（CA 125）
timeFrame: 2019.01.01-2019.12.31
measure: the positive rate of carbohydrate antigen 72-4（CA 72-4）
timeFrame: 2019.01.01-2019.12.31
measure: the positive rate of carbohydrate antigen 15-3（CA 15-3）
timeFrame: 2019.01.01-2019.12.31
measure: the positive rate of carbohydrate antigen 242（CA 242）
timeFrame: 2019.01.01-2019.12.31
measure: the positive rate of squamous cell carcinoma antigen（SCC）
timeFrame: 2019.01.01-2019.12.31
measure: the positive rate of Cytokeratin 19 fragment 21-1（CYFRA21-1）
timeFrame: 2019.01.01-2019.12.31
measure: the positive rate of total prostate-specific antigen（ TPSA）
timeFrame: 2019.01.01-2019.12.31
measure: the positive rate of free prostate-specific antigen（ FPSA）
timeFrame: 2019.01.01-2019.12.31
measure: the positive rate of neuron specific enolase（ NSE）
timeFrame: 2019.01.01-2019.12.31
Secondary outcomes:
measure: age
timeFrame: 2019.01.01-2019.12.31
measure: the measured value of systolic blood pressure (SBP)
timeFrame: 2019.01.01-2019.12.31
measure: the measured value of diastolic blood pressure (DBP)
timeFrame: 2019.01.01-2019.12.31
measure: the measured value of fasting bood glucose (FBG)
timeFrame: 2019.01.01-2019.12.31
measure: the measured value of total cholesterol (TC)
timeFrame: 2019.01.01-2019.12.31
measure: the measured value of Triglyceride (TG)
timeFrame: 2019.01.01-2019.12.31
measure: the measured value of high density lipoprotein-cholesterol (HDL-C)
timeFrame: 2019.01.01-2019.12.31
measure: the measured value of low density lipoprotein-cholesterol (LDL-C)
timeFrame: 2019.01.01-2019.12.31
measure: the measured value of height
timeFrame: 2019.01.01-2019.12.31
measure: the measured value of weight
timeFrame: 2019.01.01-2019.12.31
measure: Body Mass Index (BMI)
timeFrame: 2019.01.01-2019.12.31
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Third Hospital
Study officials:
affiliation: Peking University Third Hospital
name: Wei Zhao, doctorate
role: STUDY_DIRECTOR
References:
citation: Welch HG, Albertsen PC. Reconsidering Prostate Cancer Mortality - The Future of PSA Screening. N Engl J Med. 2020 Apr 16;382(16):1557-1563. doi: 10.1056/NEJMms1914228. No abstract available.